1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
BML, Inc.

BML, Inc.

4694.T
BML, Inc.JP flagTokyo Stock Exchange
3,655.00
JPY
+20.00
- -
137.00BMarket Cap
BML, Inc.
4694.T
(Tokyo Stock Exchange)

Recent

price

3,655.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1,902.13
2,171.21
2,227.55
2,331.82
2,457.93
2,566.51
2,618.56
2,669.04
2,750.18
2,864.53
3,410.21
4,594.86
4,051.85
3,539.64
3,672.26
- -
1,741.49
Revenue per Share
84.65
56.33
87.3
117.48
91.2
127.69
140.01
140.81
156.05
151.26
337.43
833.22
395.83
154.81
160.62
- -
68.76
Basic EPS, GAAP
126.22
105.26
153.23
183.91
190.53
214.62
166.52
186.36
203.57
205.57
378.43
951.19
134.21
-166.28
-21.77
- -
- -
Free Cash Flow per Basic Share
22.49
19.99
19.99
19.99
27.5
32.49
32.48
34.97
36.49
39.41
44.99
85.32
126.13
100.06
89.99
- -
- -
Dividend per Share
963.03
994.72
1,061.86
1,159.21
1,236.69
1,330.24
1,437.65
1,542.04
1,659.28
1,788.54
2,147.58
2,877
3,161.53
3,226.92
3,296.24
- -
3,276.25
Book Value per Share
1,039.18
1,042.97
1,131.57
1,258.23
1,348.56
1,450.2
1,580.32
1,705
1,821.03
1,812.24
2,198
2,906.76
3,105.2
3,215.89
3,302.75
- -
3,262.06
Tangible Book Value per Share
42
42
42
42
42
42
42
43
43
42
41
40
39
39
39
- -
39
Basic Weighted Avg Shares
80,762
92,201
94,608
99,047
104,404
109,024
111,243
113,502
117,129
120,732
138,571
186,067
159,462
137,964
143,191
150,262
67,855
Sales/Revenue/Turnover
8.2
5.75
7.02
8.27
6.68
7.73
8.39
8.23
8.92
8.09
14.39
26.28
15.01
6.64
6.54
6.94
5.96
Operating Margin (%)
4,581
5,836
5,730
5,490
5,979
5,763
5,160
5,331
5,020
5,043
5,365
5,801
6,257
6,700
7,716
9,121
- -
Depreciation Expense
3,594
2,392
3,708
4,990
3,874
5,424
5,948
5,988
6,646
6,375
13,711
33,741
15,578
6,034
6,263
7,748
2,679
Net Income, GAAP
44.12
54.84
42.88
37.57
41.31
33.57
32.72
34.22
34.15
33.18
31.99
31.1
33.19
34.23
32.71
33.18
35.66
Effective Tax Rate (%)
4.45
2.59
3.92
5.04
3.71
4.98
5.35
5.28
5.67
5.28
9.89
18.13
9.77
4.37
4.37
5.16
3.95
Profit Margin (%)
18,095
17,698
22,015
26,533
29,515
35,348
39,960
44,081
49,554
47,574
58,543
85,048
87,494
73,329
64,664
60,820
66,373
Working Capital
1,909
2,287
2,237
2,286
2,131
1,983
2,139
2,048
2,257
2,200
2,037
2,136
2,787
3,732
3,659
3,170
- -
LT Debt
47,136
49,694
52,941
57,654
61,966
65,205
70,644
76,220
81,124
80,420
93,121
121,681
126,748
130,137
133,770
132,126
131,986
Total Equity
7.36
4.42
6.6
8.37
6.31
8.19
8.61
7.83
8.2
7.59
14.47
28.1
11.88
4.51
4.55
4.97
1.99
Return on Invested Capital (%)
8.12
4.74
6.97
8.74
6.27
8.3
8.47
7.96
8.21
7.42
14.77
29.77
11.64
4.38
4.46
5.51
2.02
Return on Capital (%)
9.08
5.75
8.49
10.58
7.61
9.95
10.12
9.46
9.76
8.73
16.86
33.12
12.93
4.82
4.93
6.06
2.12
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
1,533
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
3,732
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
39
- -
39
Market Capitalization
113,382
112,099
103,332

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
107,977
- -
101,452
Cash, Cash Equivalents & STI
74,114
- -
67,588
Accounts Receivable, Net
24,978
- -
26,204
Inventories
4,586
- -
4,403
Total Current Liabilities
34,648
- -
35,079
Payables & Accruals
- -
- -
- -
ST Debt
1,533
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.66%
7.81%
-1.23%
Free Cash Flow
-151.64%
-318.57%
-1,347.47%
Net Income, GAAP
19.08%
11.7%
23.71%
Sales/Revenue/Turnover
4.04%
3.05%
4.94%
Total Cash Common Dividend
- -
28.62%
41.89%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
35,272
34,837
35,106
32,749
137,964
2025
- -
- -
- -
- -
143,191
2026
- -
- -
- -
- -
150,262

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
46.08
- -
- -
- -
154.81
2025
- -
- -
- -
- -
160.62
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
100.06
2025
- -
- -
- -
- -
89.99
2026
- -
- -
- -
- -
- -
Similar Companies
Stratec SE (STSEY)
Optigenex Inc. (OPGX)
DiaSorin S.p.A. (DIA.MI)
WuXi XDC Cayman Inc (2268.HK)
Thyrocare Technologies Limited (THYROCARE.NS)
RushNet, Inc. (RSHN)
Business
BML, Inc. (4694.T) provides clinical laboratory testing services and related offerings to medical institutions throughout Japan. The company offers routine biochemical and hematological tests; special tests including tumor markers, infectious diseases, hormones, cellular immunity, genetics, and bacteriology; microbiological testing for food sanitation and environmental analysis; automated systems such as Frontier for pre-testing specimen sorting and dispensing and Symphony for chemistry and hematology analysis; medical information systems encompassing electronic medical charts and laboratory information systems; genome analysis services; and additional services like food sanitation testing, environmental hygiene monitoring, and pharmaceutical consulting. Founded in 1955 and headquartered in Tokyo, BML operates a nationwide network of over 100 sales offices, regional laboratories, and the central BML General Laboratory, processing tests for approximately 300,000 patients daily across more than 4,000 items. The company maintains rigorous quality controls with ISO 15189 accreditation for its general laboratory and ISO 27001 for information security, serving hospitals, clinics, and pharmaceutical entities primarily within Japan. Recent developments include ongoing enhancements to next-generation sequencing technologies for genomic testing in infectious diseases, cancer, and hereditary conditions, alongside expansions in automation and regional laboratory networks to bolster community-based services.